Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Biomea Fusion Inc

Healthcare US BMEA

1.23USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

1.221.28
LowHigh

52 Week Range

0.873.08
LowHigh

Fundamentals

  • Previous Close 1.23
  • Market Cap138.09M
  • Volume435187
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-79.89800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -61.79700M -138.42600M -117.25500M -81.82800M -41.56700M
Minority interest - - - - -
Net income -61.79700M -138.42600M -117.25500M -80.02200M -41.21800M
Selling general administrative 19.33M 25.98M 23.59M 20.92M 13.67M
Selling and marketing expenses - - 4.20M - -
Gross profit -1.40900M -1.74800M -4.20100M - -
Reconciled depreciation 1.41M 1.75M 1.51M 0.69M 0.25M
Ebit -81.30700M -144.07000M -126.13500M -84.32500M -41.91600M
Ebitda -79.89800M -142.32200M -124.62000M -83.63400M -41.66700M
Depreciation and amortization 1.41M 1.75M 1.51M 0.69M 0.25M
Non operating income net other - - - 1.81M -
Operating income -81.30700M -144.07000M -126.13500M -83.63400M -41.66700M
Other operating expenses 81.31M 144.07M 126.14M 83.63M 41.67M
Interest expense - - - -1.80600M 0.10M
Tax provision - - - - -
Interest income 1.86M 5.64M 8.88M 1.81M 0.10M
Net interest income 1.86M 5.64M 8.88M 1.81M 0.10M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -1.80600M -0.34900M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 79.90M 144.07M 126.14M 83.63M 41.67M
Cost of revenue 1.41M 1.75M 4.20M - -
Total other income expense net 19.51M 5.64M 8.88M 1.81M 0.10M
Discontinued operations - - - - -
Net income from continuing ops -61.79700M -138.42600M -117.25500M -81.82800M -41.56700M
Net income applicable to common shares - - - -81.82800M -41.56700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 58.57M 79.94M 199.93M 129.31M 185.71M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.24M 10.05M 2.31M 4.77M 3.04M
Total liab 29.02M 28.36M 30.69M 20.77M 6.92M
Total stockholder equity 29.55M 51.57M 169.24M 108.54M 178.78M
Deferred long term liab - - - - -
Other current liab 6.41M 6.66M 13.54M 11.66M 0.48M
Common stock 0.00700M 0.00400M 0.00400M 0.00300M 0.00300M
Capital stock 0.00700M 0.00400M 0.00400M 0.00300M 0.00300M
Retained earnings -449.04800M -387.25100M -248.82500M -131.57000M -49.74200M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - 1.58M
Cash 55.81M 58.28M 176.87M 113.40M 175.74M
Cash and equivalents - - - - -
Total current liabilities 11.10M 21.67M 22.86M 19.10M 4.64M
Current deferred revenue - - - - 2.26M
Net debt -54.22300M -49.50800M -166.57000M -111.11500M -172.89300M
Short term debt 1.46M 2.08M 2.47M 0.62M 0.56M
Short long term debt - - - - -
Short long term debt total 1.59M 8.77M 10.30M 2.29M 2.85M
Other stockholder equity 478.59M 438.82M 418.06M 240.11M 42.83M
Property plant equipment - - - 5.84M 5.69M
Total current assets 58.05M 68.33M 179.18M 117.82M 176.56M
Long term investments - - 0.00000M 0.00000M 1.88M
Net tangible assets - - - 108.54M 178.78M
Short term investments - - 0.00000M 1.15M 27.78M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.23M 12.93M 6.85M 6.83M 1.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.00100M -0.01000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -131.57000M -49.74200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.37M 0.99M 2.46M 3.50M 1.58M
Deferred long term asset charges - - - - -
Non current assets total 0.52M 11.61M 20.75M 11.49M 9.14M
Capital lease obligations 1.59M 8.77M 10.30M 2.29M 2.85M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -0.36200M -2.22000M 28.37M -30.18400M
Change to liabilities - - - 11.87M 0.64M
Total cashflows from investing activities - -0.36200M -2.22000M 27.34M -33.35500M
Net borrowings - - 0.00000M - -0.03600M
Total cash from financing activities 67.90M 1.67M 163.80M 1.24M 153.19M
Change to operating activities - - - - -2.21400M
Net income -61.79700M -138.42600M -117.25500M -81.82800M -41.56700M
Change in cash -2.46700M -118.58800M 64.99M -33.83700M 84.39M
Begin period cash flow 58.65M 177.24M 112.25M 146.09M 61.70M
End period cash flow 56.18M 58.65M 177.24M 112.25M 146.09M
Total cash from operating activities -70.37100M -119.89400M -96.59200M -62.41700M -35.43800M
Issuance of capital stock 67.75M 0.00000M 161.80M 0.00000M 152.75M
Depreciation 1.41M 1.75M 1.51M 0.69M 0.25M
Other cashflows from investing activities - -0.36200M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 1.24M 153.22M
Other cashflows from financing activities - 1.67M 2.00M 27.34M 0.43M
Change to netincome - - - 10.34M 7.45M
Capital expenditures 0.00000M 0.36M 3.37M 1.03M 3.17M
Change receivables - - - - -
Cash flows other operating - - - -3.63400M -3.62000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -33.83700M 84.39M
Change in working capital -3.69800M -5.14800M 2.33M 7.67M -1.57400M
Stock based compensation 9.52M 19.09M 14.13M 10.34M 6.23M
Other non cash items -15.80500M 4.59M 2.69M 0.71M 0.70M
Free cash flow -70.37100M -120.25600M -99.96200M -63.44700M -38.60900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BMEA
Biomea Fusion Inc		 - -% 1.23 - - - 5.01 -3.7541
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.

Biomea Fusion Inc

1599 Industrial Road, San Carlos, CA, United States, 94070

Key Executives

Name Title Year Born
Mr. Thomas Andrew Butler Co-Founder, Chairman & CEO 1981
Mr. Ramses M. Erdtmann Co-Founder, Pres, COO & Director 1963
Mr. Franco Valle CFO & Principal Accounting Officer 1981
Mr. Heow Tan Chief Technology & Quality Officer 1959
Ms. Naomi Cretcher Chief People Officer NA
Dr. Thorsten Kirschberg Ph.D. Exec. VP of Chemistry 1970
Dr. Stephan Morris M.D. Chief Medical Officer NA
Mr. Ravi Upasani Sr. VP of Intellectual Property NA
Mr. Ramses M. Erdtmann Co-Founder, President, COO & Director 1963
Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Chemistry 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions